Translating Human Genetics into Novel Treatment Targets for Schizophrenia

Human genetics is a rational starting point for target identification in drug discovery, yet this approach has found little application in neuroscience. Recent large-scale analyses have begun to identify robust genetic loci for schizophrenia, providing an opportunity to derive novel drug targets. He...

Full description

Saved in:
Bibliographic Details
Published inNeuron (Cambridge, Mass.) Vol. 84; no. 3; pp. 537 - 541
Main Authors Schubert, Christian R., Xi, Hualin S., Wendland, Jens R., O’Donnell, Patricio
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 05.11.2014
Elsevier Limited
Subjects
Animals
Drug Discovery
Genetic Predisposition to Disease
Genetics
Genetics, Medical
Genomics
Humans
Pharmaceutical industry
R&D
Research & development
Schizophrenia - genetics
Schizophrenia - therapy
Translational Medical Research - methods
Online AccessGet full text

Cover

More Information
Summary:Human genetics is a rational starting point for target identification in drug discovery, yet this approach has found little application in neuroscience. Recent large-scale analyses have begun to identify robust genetic loci for schizophrenia, providing an opportunity to derive novel drug targets. Here, we summarize a strategy for applying human genetics to neuroscience drug discovery. Human genetics is a rational starting point for target identification in drug discovery, yet this approach has found little application in neuroscience. Recent large-scale analyses have begun to identify robust genetic loci for schizophrenia, providing an opportunity to derive novel drug targets. Here, Schubert et al. summarize a strategy for applying human genetics to neuroscience drug discovery.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0896-6273
1097-4199
DOI:10.1016/j.neuron.2014.10.037